Bicalutamide: In early-stage prostate cancer

Drugs

Volumn 62, Issue 17, 2002, Pages 2471-2479

  Carswell, Christopher I ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE;

BONE METASTASIS; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; FOLLOW UP; HUMAN; MONOTHERAPY; MORTALITY; PHYSICAL CAPACITY; PROSTATE CARCINOMA; PROSTATECTOMY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; REDUCTION; REVIEW;

EID: 0036448932     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262170-00006     Document Type: Review

References (31)

1. American Cancer Society. 2000 Facts and Figures. Selected Cancers: Prostate [Online]. Available from URL: http://www.cancer.org/statistics/cff2000/selectedcancers.html [Accessed 2002 May 30]. 2000
2. Anderson J. Bicalutamide treatment for locally advanced prostate cancer. Hosp Med 2000 Sep; 61 (9): 660-3
3. Fitzpatrick JM, New developments in the pharmacological management of prostate cancer. BJU Int 2000 Apr; 85 Suppl. 2: 31-7
4. National Cancer Institute. Prostate Cancer: Treatment. Stage Information [Online]. Available from URL: http://www.cancer.gov [Accessed 2002 Jun 10]
5. Vicini FA, Kestin LL, Stromberg JS, et al. Brachytherapy boost techniques for locally advanced prostate cancer. Oncology 1999 Apr; 13: 491-503
6. Pisters LL. The challenge of locally advanced prostate cancer. Semin Oncol 1999 Apr; 26: 202-16
7. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol 1995; 154: 2144-8
8. Roach III M, Lu J, Pilepich MV, et al. Long-term survival after radiotherapy alone: Radiation therapy oncology group prostate cancer trials. J Urol 1999: 161: 864-8
9. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281 (17): 1591-7
10. Reese DM. Choice of hormonal therapy for prostate cancer. Lancet 2000 Apr 29; 355: 1474-5
11. Goa KL, Spencer CM. Bicalutamide in advanced prostate cancer. A review. Drugs Aging 1998 May; 12 (5): 401-22
12. Casodex International Prescribing Information. Cheshire, UK: Astra Zeneca, 2000 Mar
13. Masiello D, Cheng S, Bubley GJ, et al. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002 Jul 19; 277: 26321-6
14. Tyrrell CJ, Denis L, Newling D, et al. Casodex™ 10-200 mg daily used as monotherapy for the treatment of patients with advanced prostate cancer. Eur Urol 1998; 33: 39-53
15. Cockshott ID, Cooper KJ, Sweetmore DS, et al. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 1990; 18 Suppl 3: 10-7
16. Cockshott ID, Oliver SD, Young JJ, et al. The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. Biopharm Drug Dispos 1997 Aug; 18 (6): 499-507
17. McKillop D, Boyle GW, Cockshott ID, et al. Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 1993 Nov; 23 (11): 1241-53
18. Wirth M, Tyrrell C, Wallace M, et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001 Aug; 58: 146-51
19. See WA, Wirth MP, McLeod DG, et al. Bicalutamide (Casodex) as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the early prostate cancer program. J Urol 2002; 168 (2): 429-35
20. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998 Mar; 51 (3): 389-96
21. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 Years of followup. J Urol 2000 Nov: 164 (5): 1579-82
22. See W, McLeod DG, Wirth M. et al. Bicalutamide (Casodex) 150 mg as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer [abstract]. J Urol 2001 May; 165 (Abstr. Suppl.): 389
23. Iversen P, Tammela TLJ, Vaage S, et al. A randomised comparison of bicalutamide ("Casodex") 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First Report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol 2002 Sep; 42 (3): 204-11
24. See WA, Mcleod D, Iverson P, et al. The bicalutamide early prostate cancer program: Demography. Urol Oncol 2001; 6: 43-7
25. Gleason DF, Mellinger GT. and the Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974 Jan; 111 (1): 58-64
26. Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: A therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. Br J Urol Int 2001; 87: 47-56
27. Tyrell CJ, Blake GM, Iversen P, et al. Casodex may preserve bone mineral density of patients with advanced prostate cancer [abstract]. Br J Urol Int 2000; 86 Suppl. 3: M6.1.09
28. Sieber PR, Keiller DL, Kahnoski RJ, et al. Bone Mineral Density is Maintained During Bicalutamide ('Casodex') Treatment [Abstract No 783][Online]. Available from URL: http://www.asco.org [Accessed 2002 Oct 9]
29. AstraZeneca. Casodex 150 International Data Sheet [Online]. Available from http://www.prostateline.com [Accessed 2002 June 6]
30. Casodex prostate cancer monotherapy survival is similar to castration - U.K. FDC Pink 1999 Jul 5; 61: 15
31. AstraZeneca. AstraZeneca receives FDA priority review for CASODEX (R) 150mg, for early stage prostate cancer. Media Rel 2002 Feb 20, 2